Heron Therapeutics Inc (HRTX)
3.00
+0.19
(+6.76%)
USD |
NASDAQ |
May 15, 16:00
3.00
0.00 (0.00%)
After-Hours: 20:00
Heron Therapeutics Cash from Financing (Quarterly): 0.011M for March 31, 2024
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 0.011M |
| December 31, 2023 | 0.199M |
| September 30, 2023 | 53.80M |
| June 30, 2023 | 0.319M |
| March 31, 2023 | -0.208M |
| December 31, 2022 | 0.439M |
| September 30, 2022 | 74.94M |
| June 30, 2022 | 0.315M |
| March 31, 2022 | -0.637M |
| December 31, 2021 | 0.487M |
| September 30, 2021 | -0.071M |
| June 30, 2021 | 154.73M |
| March 31, 2021 | 0.883M |
| December 31, 2020 | 5.762M |
| September 30, 2020 | 0.524M |
| June 30, 2020 | 2.312M |
| March 31, 2020 | 0.507M |
| December 31, 2019 | 165.13M |
| September 30, 2019 | 3.914M |
| June 30, 2019 | 10.85M |
| March 31, 2019 | 6.539M |
| December 31, 2018 | 3.061M |
| September 30, 2018 | -19.87M |
| June 30, 2018 | 370.42M |
| March 31, 2018 | 3.997M |
| Date | Value |
|---|---|
| December 31, 2017 | 146.57M |
| September 30, 2017 | 5.178M |
| June 30, 2017 | -23.62M |
| March 31, 2017 | 165.60M |
| December 31, 2016 | 1.484M |
| September 30, 2016 | 50.96M |
| June 30, 2016 | 2.476M |
| March 31, 2016 | 2.53M |
| December 31, 2015 | 1.759M |
| September 30, 2015 | 1.603M |
| June 30, 2015 | 131.75M |
| March 31, 2015 | 2.878M |
| December 31, 2014 | 0.341M |
| September 30, 2014 | 0.518M |
| June 30, 2014 | 60.29M |
| March 31, 2014 | 0.958M |
| December 31, 2013 | 59.48M |
| September 30, 2013 | 1.079M |
| June 30, 2013 | 0.054M |
| March 31, 2013 | 0.612M |
| December 31, 2012 | 0.009M |
| September 30, 2012 | 50.49M |
| June 30, 2012 | 3.013M |
| March 31, 2012 | 0.00 |
| December 31, 2011 | -0.183M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-0.637M
Minimum
Mar 2022
165.13M
Maximum
Dec 2019
23.71M
Average
0.5155M
Median
Cash from Financing (Quarterly) Benchmarks
| United Therapeutics Corp | -1.068B |
| Esperion Therapeutics Inc | 90.61M |
| Aldeyra Therapeutics Inc | 0.0182M |
| Ocular Therapeutix Inc | 321.22M |
| Alpine Immune Sciences Inc | 19.35M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -9.516M |
| Cash from Investing (Quarterly) | 1.278M |
| Free Cash Flow | -43.40M |
| Free Cash Flow Per Share (Quarterly) | -0.0629 |
| Free Cash Flow to Equity (Quarterly) | -9.752M |
| Free Cash Flow Yield | -10.20% |